Nonetheless, TF-NGR remains the only drug with the capacity to induce tumor vascular collapse associated with a marked reduction in tumor growth, and it is currently being tested in a phase I clinical trial (NCT02902237) [2]. The gene discussed is TF; the disease is neoplasm.